Head to Head Review: Portage Biotech (NASDAQ:ALP) and VivoPower PLC Ordinary Shares (NASDAQ:VIVO)

VivoPower PLC Ordinary Shares (NASDAQ:VIVO) and Portage Biotech (NASDAQ:ALP) are both small-cap technology companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares VivoPower PLC Ordinary Shares and Portage Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
VivoPower PLC Ordinary Shares	N/A	N/A	N/A
Portage Biotech	N/A	N/A	N/A

Volatility and Risk

VivoPower PLC Ordinary Shares has a beta of -0.69, indicating that its stock price is 169% less volatile than the S&P 500. Comparatively, Portage Biotech has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.

Insider and Institutional Ownership

15.8% of VivoPower PLC Ordinary Shares shares are owned by institutional investors. Comparatively, 13.4% of Portage Biotech shares are owned by institutional investors. 9.1% of VivoPower PLC Ordinary Shares shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares VivoPower PLC Ordinary Shares and Portage Biotech”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VivoPower PLC Ordinary Shares	$61,000.00	903.59	-$12.79 million	N/A	N/A
Portage Biotech	$97,000.00	39.34	-$38.63 million	($8.18)	-0.02

VivoPower PLC Ordinary Shares has higher earnings, but lower revenue than Portage Biotech.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for VivoPower PLC Ordinary Shares and Portage Biotech, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VivoPower PLC Ordinary Shares	1	0	1	0	2.00
Portage Biotech	1	1	0	0	1.50

VivoPower PLC Ordinary Shares currently has a consensus price target of $10.00, indicating a potential upside of 127.27%. Portage Biotech has a consensus price target of $0.25, indicating a potential upside of 53.75%. Given VivoPower PLC Ordinary Shares’ stronger consensus rating and higher probable upside, equities research analysts clearly believe VivoPower PLC Ordinary Shares is more favorable than Portage Biotech.

Summary

VivoPower PLC Ordinary Shares beats Portage Biotech on 7 of the 9 factors compared between the two stocks.

About VivoPower PLC Ordinary Shares

VivoPower PLC is engaged in building, owning, and leasing powered land and data center infrastructure for AI compute applications. The group delivers specialized infrastructure solutions across the AI Data Centers, Power-to-X, and Electric Mobility. It is develop and operated infrastructure that enables sovereign nations and institutional partners to secure control over power, data, and national intelligence, supporting AI, compute-intensive workloads, and energy transition use cases.

About Portage Biotech

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company’s product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.